Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2021-06-04, Stock:LLY, The news for the past five days is as follows:
2021-05-27: NEWS1: Florida Cruise Tests Rules; U.K. Opening in Doubt: Virus Update.NEWS2: Justice Department Opens Probe In Presumed lapses at Eli Lilly's COVID-19 Drug Plant: Reuters.NEWS3: Exclusive-U.S. opens criminal probe into alleged lapses at Eli Lilly plant - sources.NEWS4: Eli Lilly Slapped With DoJ Subpoena Over COVID-19 Drug Manufacturing Plant: Reuters.NEWS5: Lilly (LLY) Up 11.3% Since Last Earnings Report: Can It Continue?.NEWS6: New Strong Sell Stocks for May 27th.NEWS7: Vir Biotech (VIR)/Glaxo COVID-19 Drug Gets FDA Emergency Nod.NEWS8: UPDATE 2-Eli Lilly receives DoJ subpoena over COVID-19 drug manufacturing plant.NEWS9: Eli Lilly receives DoJ subpoena over COVID-19 drug manufacturing plant.
2021-05-28: NEWS1: The FDA authorized the third antibody infusion therapy. Here’s why Vir and GSK say the U.S. still needs COVID-19 treatments.NEWS2: U.S. stops distributing Lilly's COVID-19 antibody therapy in six states, instead recommends Regeneron's treatment.NEWS3: Eli Lilly Receives DOJ Subpoena Related to Manufacturing Site.
2021-06-01: NEWS1: OLUMIANT® Improved Pain, Physical Function and Morning Joint Stiffness in Rheumatoid Arthritis in Phase 3 Post-Hoc Analyses.NEWS2: Taltz® Showed Consistent, Long-Term Improvement in Key Signs and Symptoms of Axial Spondyloarthritis Through Two Years in Phase 3 Study.
2021-06-02: NEWS1: Lilly's Olumiant Found to Lower Pain In Late-Stage Rheumatoid Arthritis Trial.NEWS2: Thirty Madison Vaults to Unicorn Status, Raises $140 Million.NEWS3: 15 Most Valuable Pharmaceutical Companies In The World.
2021-06-03: NEWS1: Lilly to Participate in Goldman Sachs Healthcare Conference.NEWS2: Lilly Reveals Critical Barriers to Optimal Migraine Care and Insights From Novel Clinical and Patient-Centric Real-World Evidence, Supporting Lilly's Preventive and Acute Treatment Portfolio at AHS 2021.

Answer: Decrease